Induction of myeloid-derived suppressor cells (MDSCs) by mycobacteria vaccines

分枝杆菌疫苗诱导骨髓源性抑制细胞 (MDSC)

基本信息

项目摘要

Vaccination against tuberculosis (TB) is currently performed with Mycobacterium bovis Bacille-Calmette-Guérin (BCG). However, the protective effects are very limited. Vaccines based on the major human pathogen Mycobacterium tuberculosis (Mtb) or its antigens are still not available, despite enormous efforts. The reasons for this remain largely unknown. Since myeloid-derived suppressor cells (MDSCs) accumulate in patients with TB and in mice infected with live Mtb, it was possible that also killed Mtb vaccines may induce MDSCs and thereby impair vaccination success. Although Complete Freund's Adjuvant (CFA; containing heat-killed Mtb in oil) is a potent vaccine adjuvant, also immunosuppressive effects have been reported, that remain unexplained. Our published data indicated that monocytes can undergo a licensing process in vitro, which allowed their further conversion into Nos2-dependent NO releasing monocytic MDSCs (M-MDSCs). Our recently published data now indicate that the functional generation of CD11b+ Ly-6Chigh CD115+ iNOS+ M-MDSCs can be observed in vivo after Mtb vaccination, although their monocyte origin is unclear. These M-MDSC infiltrate the splenic bridging channels and white pulp where their NO production results in killing of dendritic cells (DCs), but unexpectedly not T cells. Collectively, these data reveal that Mtb booster vaccines induce M-MDSCs that kill DCs. However, several open questions remain to be addressed to better understand this phenomenon that may have impact also for clinical studies on Mtb vaccination.The objectives of this proposal are: 1) Demonstrate the conversion of monocytes into L-Mono and M-MDSC by different mycobacterial strains and compare live and dead vaccination protocols by fate mapping in vivo, 2) Demonstrate the detrimental role of live and dead vaccine-induced M-MDSCs for subsequent BCG and Mtb infections and the benefit of M-MDSC depletion during vaccination, 3) Unravel the role of the mTOR pathway specifically for M-MDSC function during mycobacterial vaccination and infection, 4) Dissect M-MDSC suppressor mechanisms of DC killing and T cell functional suppression or exhaustion after mycobacterial vaccination.
目前,结核病疫苗接种是使用牛分枝杆菌卡介苗(BCG)。然而,保护作用是非常有限的。尽管付出了巨大努力,基于人类主要病原体结核分枝杆菌(Mtb)或其抗原的疫苗仍然无法获得。造成这种情况的原因在很大程度上仍不清楚。由于髓系来源的抑制细胞(MDSCs)在结核病患者和感染活Mtb的小鼠体内积聚,因此也有可能也被灭活的Mtb疫苗诱导MDSCs,从而损害疫苗接种的成功。尽管完全弗氏佐剂(CFA;在油中含有热灭活的结核分枝杆菌)是一种有效的疫苗佐剂,但也有免疫抑制作用的报道,但原因尚不清楚。我们发表的数据表明,单核细胞在体外可以经历一个许可过程,这使得它们可以进一步转化为NOS2依赖的释放NO的单核细胞MDSCs(M-MDSCs)。我们最近发表的数据表明,在结核分枝杆菌疫苗接种后,可以在体内观察到CD11b+Ly-6 Chigh CD115+iNOS+M-MDSCs的功能生成,尽管其单核细胞来源尚不清楚。这些M-MDSC渗透到脾桥接通道和白髓,它们的NO产生导致树突状细胞(DC)的杀伤,但出乎意料的是T细胞不被杀死。总而言之,这些数据揭示了结核分枝杆菌强化疫苗诱导的M-MDSCs杀死DC。然而,为了更好地理解这一现象,也可能对结核分枝杆菌疫苗的临床研究产生影响,仍有几个有待解决的问题。本研究的目的是:1)展示不同分枝杆菌株将单核细胞转化为L-单核细胞和M-MDSC,并通过体内命运图谱比较活疫苗和死亡疫苗诱导的M-MDSC;2)证明活疫苗和死亡疫苗诱导的M-MDSC在随后的卡介苗和结核分枝杆菌感染中的不利作用以及M-MDSC在疫苗接种过程中的好处;3)揭示M-MDSC功能的mTOR通路在分枝杆菌疫苗接种和感染过程中的作用,4)分析分枝杆菌疫苗接种后M-MDSC对DC杀伤和T细胞功能抑制或耗竭的抑制机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Professor Dr. Manfred Lutz其他文献

Professor Dr. Manfred Lutz的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Professor Dr. Manfred Lutz', 18)}}的其他基金

Conversion of anergic non-regulatory into Foxp3- IL-10+ regulatory T cells by dendritic cells in vivo
体内树突状细胞将无能非调节性 T 细胞转化为 Foxp3-IL-10 调节性 T 细胞
  • 批准号:
    338949849
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
    Research Grants
Control of the homeostatic regulatory T cell pool by RelB expression in steady state migratory dendritic cells
通过稳态迁移树突状细胞中的 RelB 表达控制稳态调节 T 细胞库
  • 批准号:
    233384519
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
    Research Grants
VLA-1-dependent migration patterns and functions of monocytic myeloid-derived suppressor cells (M-MSDC) during autoimmunity and infection.
自身免疫和感染期间单核细胞骨髓源性抑制细胞 (M-MSDC) 的 VLA-1 依赖性迁移模式和功能。
  • 批准号:
    195892802
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
    Research Grants
Applikation muriner myeloider Suppressorzellen bei der Experimentellen Autoimmun-Enzephalomyelitis und bei Hautransplantationen, sowie Generierung humaner myeloider Suppressorzellen
小鼠骨髓抑制细胞在实验性自身免疫性脑脊髓炎和皮肤移植中的应用以及人骨髓抑制细胞的产生
  • 批准号:
    27645552
  • 财政年份:
    2006
  • 资助金额:
    --
  • 项目类别:
    Research Grants
Mechanismen der Induktion regulatorischer T-Zellen mittels dendritischer Zellen in vivo
使用树突状细胞体内诱导调节性 T 细胞的机制
  • 批准号:
    5409486
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
    Research Grants
Interaktion von Dendritischen Zellen und Mastzellen bei T-Helfer Typ 2 Immunantworten
2 型辅助 T 免疫反应中树突状细胞和肥大细胞的相互作用
  • 批准号:
    5369608
  • 财政年份:
    2002
  • 资助金额:
    --
  • 项目类别:
    Research Grants
Transcriptional profiling, cytokine requirement and function of myeloid-derived suppressor cells (MDSC) in the Mesocestoides corti Type 2 infection model
2 型中绦虫感染模型中骨髓源性抑制细胞 (MDSC) 的转录谱、细胞因子需求和功能
  • 批准号:
    527029760
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
    Research Grants

相似国自然基金

S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
  • 批准号:
    82070825
  • 批准年份:
    2020
  • 资助金额:
    53 万元
  • 项目类别:
    面上项目
STAT3/IDO途径参与乳腺癌髓系来源抑制细胞(MDSCs)下调T细胞免疫及相关机制探讨
  • 批准号:
    81072159
  • 批准年份:
    2010
  • 资助金额:
    32.0 万元
  • 项目类别:
    面上项目

相似海外基金

Synergistic combinations that target apoptosis induction in PTCL
针对 PTCL 细胞凋亡诱导的协同组合
  • 批准号:
    10477038
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
The Induction of Macrophage Endoplasmic Reticulum Stress by Irradiated-Tumor Derived Extracellular Vesicles Supports the Adoption of a Pro-Tumor Phenotype
辐射肿瘤源性细胞外囊泡对巨噬细胞内质网应激的诱导支持了亲肿瘤表型的采用
  • 批准号:
    10386821
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Tolerance Induction in Organ Transplantation by Myeloid-Derived Suppressor Cells through Recruitment of Regulatory T and B cells
骨髓源性抑制细胞通过募集调节性 T 细胞和 B 细胞诱导器官移植中的耐受性
  • 批准号:
    19K18066
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Synergistic combinations that target apoptosis induction in PTCL
针对 PTCL 细胞凋亡诱导的协同组合
  • 批准号:
    10673106
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Synergistic combinations that target apoptosis induction in PTCL
针对 PTCL 细胞凋亡诱导的协同组合
  • 批准号:
    10249205
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
The Induction of Macrophage Endoplasmic Reticulum Stress by Irradiated-Tumor Derived Extracellular Vesicles Supports the Adoption of a Pro-Tumor Phenotype
辐射肿瘤源性细胞外囊泡对巨噬细胞内质网应激的诱导支持了亲肿瘤表型的采用
  • 批准号:
    9760846
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
The Induction of Macrophage Endoplasmic Reticulum Stress by Irradiated-Tumor Derived Extracellular Vesicles Supports the Adoption of a Pro-Tumor Phenotype
辐射肿瘤源性细胞外囊泡对巨噬细胞内质网应激的诱导支持了亲肿瘤表型的采用
  • 批准号:
    10611841
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
The strategy for induction of mmunotolerance in liver transplantation using myeloid-derived suppressor cells
使用骨髓源性抑制细胞诱导肝移植免疫耐受的策略
  • 批准号:
    18K16306
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular mechanisms underlying the induction of myeloid-derived suppressor cells in multiple myeloma
多发性骨髓瘤中骨髓源性抑制细胞诱导的分子机制
  • 批准号:
    18K16125
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
NOVEL INNATE MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN ALLOGENEIC HCT FOR HEMOGLOBINOPATHIES
血红蛋白病同种异体 HCT 中免疫耐受诱导的新先天机制
  • 批准号:
    10067378
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了